Opko Embarks On Transition To Profitability With Discount Buy

30 Jun 2016

• By Lisa LaMotta

The life sciences company picks up Transition Therapeutics in an all-stock deal that fleshes out its pipeline.

While Opko Health Inc. now has multiple revenue-generating products across its diverse portfolio, the company is still struggling to be profitable and lacks the strong pipeline to be a major player in diseases with under-served patient populations. With that in mind, Opko is picking up Transition Therapeutics Inc. at a deep discount in hopes of padding its pipeline.

The Miami-based company is acquiring Transition in an all-stock swap worth $60m, or $1.55 per share, that is expected to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

04 Jul 2025

• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

04 Jul 2025

• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

04 Jul 2025

• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

04 Jul 2025

• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

04 Jul 2025

• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.